Oussama Wazni

Jan 20, 2025 | arrhythmiaacademy.com | Gi-Byoung Nam |Walid Saliba |Oussama Wazni |Manesh R. Patel

AF Symposium 25 - Left atrial appendage (LAA) closure using the WATCHMAN FLX device (Boston Scientific) showed lower risk of bleeding and non-inferiority in efficacy endpoints to oral anticoagulation in patients who have received or are planning to receive AF ablation.

Nov 17, 2024 | hcplive.com | Oussama Wazni |Patrick Campbell

Results of the OPTION trial, which examined use of the WATCHMAN FLX device for left atrial appendage closure (LAAC) as part of a standard post-ablation strategy in atrial fibrillation, indicate the study met both its primary safety and efficacy endpoint, with the WATCHMAN FLX device demonstrating superiority to OAC for bleeding events and noninferiority for a composite of all-cause mortality, stroke, and systemic embolism at 36 months.1 "The OPTION trial data provide clinical evidence...

Nov 16, 2024 | healio.com | Katie Kalvaitis |Richard Smith |Oussama Wazni

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: OPTION is a head-to-head trial of left atrial appendage closure with Watchman FLX vs. anticoagulation after ablation for atrial fibrillation. Strategies provided equivalent thromboembolic protection at 3 years.

Jan 12, 2024 | healio.com | Erik Swain |Richard Smith |Bruce L. Wilkoff |Oussama Wazni

You've successfully added Cardiology: Arrhythmia Disorders to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Bruce L. Wilkoff, MD, whose work showed how to extract faulty cardiac device leads safely, has died.